Tienilic acid
 | |
|---|---|
| Systematic (IUPAC) name | |
| [2,3-dichloro-4-(2-thienylcarbonyl)phenoxy]acetic acid | |
| Clinical data | |
| Legal status | Withdrawn |
| Routes | Oral |
| Pharmacokinetic data | |
| Protein binding | 95% |
| Metabolism | Hepatic |
| Half-life | 6 hours |
| Excretion | Renal and biliary |
| Identifiers | |
| CAS number | 40180-04-9 |
| ATC code | C03CC02 |
| PubChem | CID 38409 |
| ChemSpider | 35204 |
| UNII | HC95205SY4  |
| KEGG | D02386 |
| ChEMBL | CHEMBL267744 |
| Chemical data | |
| Formula | C13H8Cl2O4S |
| Mol. mass | 331.17 g/mol |
| SMILES
| |
| |
Tienilic acid (INN and BAN) or ticrynafen (USAN) is a loop diuretic drug with uric acid-lowering (uricosuric) action,[1][2] formerly marketed for the treatment of hypertension. It was approved by FDA on May 2, 1979, and withdrawn in 1982, after case reports in the United States indicated a link between the use of ticrynafen and hepatitis.[3]
Criminal charges were brought against SmithKline executives with regard to hiding data related to toxicity while gaining FDA approval. The company pleaded guilty to 14 counts of failure to report adverse reactions and 20 counts of selling a misbranded drug.[4]
Tienilic acid was found to act as a suicide substrate at the cytochrome P450 enzymes involved in drug metabolism. Unfortunately, the metabolic reaction carried out by these enzymes converted tienilic acid to a thiophene sulfoxide which proved highly electrophilic. This encouraged a Michael reaction leading to alkylation of a thiol group in the enzyme's active site. Loss of water from the thiophene sulfoxide restored the thiophene ring and resulted in tienilic acid being covalently linked to the enzyme, thus inhibiting the enzyme irreversibly.
The above explanation is a hypothesis. It is still not known (after 15 years) if the reactive intermediate which inactivates the CYP2C9 is the thiophene sulfoxide or the thiophene epoxide. The target on the protein is also not known (could be multiple). However tienilic acid is a good mechanism based inhibitor of CYP2C9 and seems to inactivate it stoichiometrically. Progress in proteomics may one day give the answer.
Recent studies indicate that in fact the primary metabolite of tienilic acid (5-OH tienilic acid) cannot be derived from a thiophene-S-oxide intermediate as was previously hypothesized. It was determined to be derived from a thiophene epoxide intermediate and this reactive intermediate is then likely a cause for the covalent binding to as well as mechanism-based inactivation of CYP2C9.[5]
References
- ↑ Schlatter, E.; Greger, R.; Weidtke, C. (1983). "Effect of "high ceiling" diuretics on active salt transport in the cortical thick ascending limb of Henle's loop of rabbit kidney. Correlation of chemical structure and inhibitory potency". Pflugers Archiv : European journal of physiology 396 (3): 210–217. PMID 6844125.
- ↑ Steele, T. H. (1979). "Mechanism of the uricosuric activity of ticrynafen". Nephron. 23 Suppl 1: 33–37. PMID 471151.
- ↑ Manier, J. W.; Chang, W. W.; Kirchner, J. P.; Beltaos, E. (1982). "Hepatotoxicity associated with ticrynafen--a uricosuric diuretic". The American journal of gastroenterology 77 (6): 401–404. PMID 7091125.
- ↑ United States v. SmithKline Beckman et al {BLR 286} Biotechnology Law Report. September–October 1984, 3(9-10): 206-214.
- ↑ Rademacher, P. M.; Woods, C. M.; Huang, Q.; Szklarz, G. D.; Nelson, S. D. (2012). "Differential Oxidation of Two Thiophene-Containing Regioisomers to Reactive Metabolites by Cytochrome P450 2C9". Chemical Research in Toxicology 25 (4): 895–903. doi:10.1021/tx200519d. PMID 22329513.
| ||||||||||||||||||||||||||||||||||||||||||